07:00 , Aug 18, 2014 |  BioCentury  |  Strategy

Breathing room

AstraZeneca plc 's acquisition of Almirall S.A. 's respiratory assets should buy the pharma time while its respiratory pipeline matures. The deal not only gives AstraZeneca a faster route to market in the COPD combination...
01:32 , Jul 31, 2014 |  BC Extra  |  Top Story

AZ to acquire Almirall's respiratory business

AstraZeneca plc (LSE:AZN; NYSE:AZN) will acquire the respiratory disease business of Almirall S.A. (Madrid:ALM) for $875 million up front and up to $1.2 billion in milestones. The business had 1H14 sales of EUR 123.5 million...
07:00 , Mar 22, 2010 |  BioCentury  |  Regulation

Last chance on LABAs

Although it's not yet possible to determine the final cost of potentially huge post-marketing studies to evaluate the safety of LABAs to treat asthma, it's clear they will not be cheap and will take resources...
08:00 , Dec 21, 2009 |  BC Week In Review  |  Company News

Almirall, Forest Laboratories deal

Almirall partnered with Forest to develop and commercialize Almirall's LAS100977 in the U.S. The once-daily long-acting adrenergic receptor beta 2 agonist (LABA) is in Phase II testing to treat asthma and chronic obstructive pulmonary disease...
02:30 , Dec 18, 2009 |  BC Extra  |  Top Story

Almirall, Forest in LABA deal

Almirall S.A. (Madrid:ALM) partnered with Forest Laboratories Inc. (NYSE:FRX) to develop and commercialize Almirall's LAS100977 in the U.S. The once-daily long-acting adrenergic receptor beta 2 agonist (LABA) is in Phase II testing to treat asthma...